To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
Summary
HR 7902 (Safeguarding Women from Chemical Abortion Act) would withdraw FDA approval for mifepristone for pregnancy termination and create a federal tort for harm from chemical abortion drugs. The bill was introduced March 12, 2026, referred to two committees, and is in early legislative stages with only 6 cosponsors. Revenue exposure for $PFE and $TEVA is immaterial to their overall financials — less than 0.1% of revenue for each. The bill has effectively no near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR 7902 is early-stage legislation with very low near-term passage probability (6 cosponsors, no committee action)
- 2.Revenue exposure to $PFE and $TEVA is immaterial — less than 0.1% of annual revenue for either company
- 3.$TEVA's 15% weekly gain and $PFE's 5% monthly decline are driven by company-specific catalysts, not abortion legislation
- 4.No federal spending is authorized — funding_amount is $0
Market Implications
This bill has negligible market implications. $PFE at $26.71 (near 52-week low of $21.97) faces headwinds from LoE on Xeljanz, Ibrance, and Eliquis patent cliffs — not from a low-revenue product like mifepristone. $TEVA at $35.26 (near 52-week high of $37.35) is rallying on positive pipeline news and AJOVY/COPAXONE generic defense. Traders should not factor HR 7902 into positions on either stock. The only scenario that would change the market calculus is a surprise markup or hearing scheduling that signals bill progression — currently no evidence of that.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Withdrawal of FDA approval for mifepristone for pregnancy termination (section 2 of bill) - directly impacts Pfizer's branded Mifeprex product
Who must act
Pfizer Inc. (manufacturer of branded mifepristone/Mifeprex)
What happens
If enacted, Pfizer would be prohibited from commercializing mifepristone for the labeled indication of pregnancy termination; remaining approved uses (Cushing's syndrome) unaffected; product effectively removed from the US abortion market
Stock impact
Mifepristone for pregnancy termination contributes an immaterial fraction of Pfizer's ~$58B annual revenue (less than 0.1%); Pfizer's primary businesses are vaccines (Comirnaty, Prevnar), oncology (Ibrance, Xtandi, Eliquis), and inflammation; no material financial impact
What the bill does
Withdrawal of FDA approval for generic mifepristone products referencing branded mifeprex (section 2(1) of bill)
Who must act
Teva Pharmaceutical Industries Ltd. (generic manufacturer of mifepristone)
What happens
Teva's authorized generic mifepristone would be withdrawn from the US market for pregnancy termination indication; no impact on Teva's non-abortion product lines (CNS, respiratory, oncology generics)
Stock impact
Teva's mifepristone generic is a low-revenue product; Teva's 2025 total revenue is approximately $16B; the entire US mifepristone market (branded + generic) is estimated at less than $50M annually; impact on Teva is immaterial
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Safeguarding Women from Chemical Abortion Act
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.